Fewer Bleeds, Smarter Steroids: Apixaban vs Rivaroxaban and CRP-Guided Steroids for Pneumonia

With Special Guest Dr. Adam JaffeIn this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Adam Jaffe to tackle two high-impact clinical questions:Is there a clear winner among DOACs? Who actually benefits from steroids in community-acquired pneumonia? Two common decisions. New data. Practice-changing implications. Articles & PubMed LinksApixaban vs Rivaroxaban for VTE (Head-to-Head RCT)New England Journal of Medicine (2026)Randomized trial (n=2,760) comparing:Apixaban vs Rivaroxaban Population:Acute VTE Excluded: active cancer, extreme obesity, other anticoagulation indications Key Findings↓ Clinically significant bleeding with apixaban ~54% relative risk reduction NNT ≈ 27 ↓ Major bleeding (0.4% vs 2.4%) No difference in: Recurrent VTE Mortality InterpretationSame efficacy Less bleeding with apixaban Takeaway→ For new starts: Apixaban is the preferred DOACpubmed: https://pubmed.ncbi.nlm.nih.gov/41812192/Corticosteroids in Community-Acquired Pneumonia (IPD Meta-analysis)LancetLarge meta-analysis (n=3,224 across 8 RCTs)Compared:Steroids vs Placebo Primary Outcome: 30-day mortalityAbsolute risk reduction: 2.2% NNT = 46 🔑 The Key Insight: CRP MattersWhen stratified by inflammation:CRP >200Mortality: 13% → 6% Absolute risk reduction ≈ 7% NNT ≈ 14 CRP <200No mortality benefit Other Findings↑ Hyperglycemia (expected) ↑ Readmissions (7% vs 3.7%) No clear signal that severity scores (PSI) identify benefit InterpretationSteroids are not for everyone Benefit appears driven by high inflammatory states Takeaway→ Consider steroids in CAP only if CRP is markedly elevated (~>200) → Routine use in all pneumonia is not supportedpubmed: https://pubmed.ncbi.nlm.nih.gov/39892408/Practice-Changing TakeawaysDOACs: Apixaban > rivaroxaban for bleeding Same clot prevention → choose apixaban for new starts Pneumonia: Steroids may reduce mortality — but only in the right patient CRP can help identify who benefits Clinical PearlsThe difference between DOACs is no longer “vibes” — we now have head-to-head data Most steroid benefit in pneumonia appears inflammatory-driven, not severity-driven CRP — often ignored — may actually guide meaningful decisions here Bottom LineIf you change nothing else this week:Start apixaban for new VTE patients In pneumonia, check a CRP — and consider steroids if >200 Fewer bleeds. Smarter steroids. Better outcomes.Support the showWant the cited articles and key takeaways? Join the email list:https://subscribe.inpatientupdate.com/